Publications by authors named "Aurelien Marabelle"

100Publications

Chemokine biology on immune checkpoint-targeted therapies.

Eur J Cancer 2020 Sep 18;137:260-271. Epub 2020 Aug 18.

INSERM U1015, Gustave Roussy, Villejuif, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.06.009DOI Listing
September 2020

Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination.

Cancer Discov 2020 Aug;10(8):1097-1099

Institut National de la Santé et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée Ligue Nationale contre le Cancer, Tumor immunology and immunotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0786DOI Listing
August 2020

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.

Nat Rev Clin Oncol 2020 Nov 7;17(11):707-715. Epub 2020 Jul 7.

Department of Medicine, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-020-0399-6DOI Listing
November 2020

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.

J Clin Oncol 2020 Aug 18;38(23):2667-2676. Epub 2020 Jun 18.

New York-Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402995PMC
August 2020

Mechanisms and therapeutic implications of hypermutation in gliomas.

Nature 2020 04 15;580(7804):517-523. Epub 2020 Apr 15.

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-020-2209-9DOI Listing
April 2020

Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.

Eur J Nucl Med Mol Imaging 2020 Sep 23;47(10):2301-2312. Epub 2020 Mar 23.

Department of Radiology, New York Presbyterian Hospital, Columbia University Medical Center, 168th Street, New York, NY, 10039, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04757-3DOI Listing
September 2020

The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.

Eur J Cancer 2020 05 12;130:39-50. Epub 2020 Mar 12.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne and Immunologie clinique, Le Kremlin-Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France; Université Paris Sud, UMR 1184, Le Kremlin Bicêtre, France; CEA, DSV/iMETI, IDMIT, Fontenay-aux-Roses, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.02.010DOI Listing
May 2020

Repurposing infectious disease vaccines for intratumoral immunotherapy.

J Immunother Cancer 2020 02;8(1)

Gustave Roussy, INSERM U1015, Université Paris-Saclay, Drug Development Department (DITEP), Gustave Roussy, 94805, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2019-000443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057427PMC
February 2020

Hyperprogression upon immunotherapy: A chance for (hyper-)progress.

Eur J Cancer 2020 02 13;126:139-140. Epub 2020 Jan 13.

Drug Development Department (DITEP), Gustave Roussy, Paris- Saclay University, Villejuif, France; Medical School, Paris-Saclay University, Paris-Sud University, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.12.011DOI Listing
February 2020

[Toxicities of immune checkpoint inhibitors and their management].

Med Sci (Paris) 2019 Dec 6;35(12):949-956. Epub 2020 Jan 6.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/2019191DOI Listing
December 2019

Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Nat Rev Clin Oncol 2020 01 8;17(1):49-64. Epub 2019 Oct 8.

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0272-7DOI Listing
January 2020

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection.

Clin Cancer Res 2019 11 23;25(21):6283-6294. Epub 2019 May 23.

Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1800DOI Listing
November 2019

Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.

Am J Ophthalmol 2019 06 15;202:109-117. Epub 2019 Feb 15.

Service d'Ophtalmologie, DHU Vision & Handicaps, Centre de référence pour les maladies rares en ophtalmologie (OPHTARA), Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France; Université Paris-Sud, Le Kremlin-Bicêtre, France; Immunology of Viral Infections and Autoimmune Diseases, INSERM U1184, Le Kremlin-Bicêtre, France; Department of Immunology of Viral and Auto-immune Disease, UMR1184, CEA, CEA, DSV/iMETI, IDMIT, Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2019.02.012DOI Listing
June 2019

Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.

Eur J Cancer 2019 02 14;108:111-119. Epub 2019 Jan 14.

Department of Urology, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Suresnes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.010DOI Listing
February 2019

Autres immunothérapies.

Bull Cancer 2018 Dec;105 Suppl 1:S121-S131

Gustave Roussy, Université Paris-Saclay, département d'innovation thérapeutique et d'essais précoces, Villejuif, F-94805, France; Inserm U1015, Gustave Roussy, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(18)30397-7DOI Listing
December 2018

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Lancet Haematol 2019 Jan 4;6(1):e48-e57. Epub 2018 Dec 4.

Service de Médecine Interne and Immunologie Clinique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France; Université Paris Sud, Centre de Recherche en Immunologie des Infections Virales et des Maladies Auto-Immunes, INSERM, Le Kremlin-Bicêtre, France; Division d'Immunovirologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Fontenay-aux-Roses, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30175-3DOI Listing
January 2019

Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"

J Hepatol 2019 03 5;70(3):566-567. Epub 2018 Dec 5.

AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.11.016DOI Listing
March 2019

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Letter.

Clin Cancer Res 2019 06 4;25(11):3468. Epub 2018 Dec 4.

INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3740DOI Listing
June 2019

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.

Br J Cancer 2019 01 9;120(1):3-5. Epub 2018 Nov 9.

Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0294-4
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0294-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325162PMC
January 2019

Hyperprogressive disease: recognizing a novel pattern to improve patient management.

Nat Rev Clin Oncol 2018 12;15(12):748-762

Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0111-2
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0111-2DOI Listing
December 2018

Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study".

J Hepatol 2018 12 5;69(6):1397-1398. Epub 2018 Oct 5.

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.09.006DOI Listing
December 2018

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Lancet Oncol 2018 09 14;19(9):1180-1191. Epub 2018 Aug 14.

Gustave Roussy-CentraleSupélec-Therapanacea Centre of Artificial Intelligence in Radiation Therapy and Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Radiomics Team, Molecular Radiotherapy INSERM U1030, Paris-Sud University, Gustave Roussy Cancer Campus, and University of Paris-Saclay, Villejuif, France; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30413-3DOI Listing
September 2018

Reply to: "Mortality due to immunotherapy related hepatitis".

J Hepatol 2018 10 7;69(4):978-979. Epub 2018 Aug 7.

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, F-94800, France, DHU Hepatinov, Villejuif, France; Inserm, Unité 1193, Villejuif, Université Paris-Saclay, F-94800, France; Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, Villejuif, F-94800, France; Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183226
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.07.009DOI Listing
October 2018

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

J Hepatol 2018 08;69(2):550-551

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM, Unité 1193, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, DHU Hepatinov, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.04.019DOI Listing
August 2018

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

Eur J Cancer 2018 06 23;96:91-104. Epub 2018 Apr 23.

Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris-Saclay, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.006DOI Listing
June 2018

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

J Hepatol 2018 06 8;68(6):1181-1190. Epub 2018 Feb 8.

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire; Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay; Inserm, Unité 1193, Université Paris-Saclay; Hepatinov, Villejuif, F-94800, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.01.033DOI Listing
June 2018

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Eur J Cancer 2018 03 3;92:1-10. Epub 2018 Feb 3.

Drug Development Department, Gustave Roussy, Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France; Gustave Roussy Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.020DOI Listing
March 2018

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Eur J Cancer 2018 03;91:136-144

Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Gustave Roussy, Université Paris-Saclay, Département D'hématologie, Villejuif F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.015DOI Listing
March 2018

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Eur J Cancer 2018 03 10;91:21-29. Epub 2018 Jan 10.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275, Le Kremlin-Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276, Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276, Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265, Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.008DOI Listing
March 2018

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.

JAMA Dermatol 2018 01;154(1):113

Department of Hematology, CHU Rennes, Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2017.4421DOI Listing
January 2018

Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma.

Cancer Cell 2017 10;32(4):427-443.e8

University of Lyon, University of Lyon 1 Claude Bernard Lyon1, NeuroMyoGene Institute, CNRS UMR5310, INSERM U1217, 16 rue Raphael Dubois, F-69000 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.09.006DOI Listing
October 2017

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

Eur J Cancer 2017 11 13;85:155-157. Epub 2017 Sep 13.

Drug Development Department (DITEP), Gustave Roussy, and University Paris-Sud, Villejuif, France; INSERM U981, Gustave Roussy, University Paris XI, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.049DOI Listing
November 2017

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Eur J Cancer 2017 11 9;85:67-77. Epub 2017 Sep 9.

Département des Innovations Thérapeutiques et des Essais Précoces, Gustave Roussy, 114 Rue Edouard-Vaillant, F-94805 Villejuif, France; Département d'Oncologie Médicale, Institut Jules Bordet, rue Héger Bordet 1, B-1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.08.014DOI Listing
November 2017

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

Eur J Cancer 2017 10 29;84:290-303. Epub 2017 Aug 29.

UMR8200 - CNRS, Stabilité Génétique et Oncogenèse, France; Gustave Roussy Cancer Campus, F-94805, Villejuif, France; Université Paris Saclay, Paris Sud - Orsay, F-91400, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049173114
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2017.07.026DOI Listing
October 2017

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Eur J Cancer 2017 10 18;84:202-211. Epub 2017 Aug 18.

Drug Development Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.033DOI Listing
October 2017

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Eur J Cancer 2017 09 10;82:34-44. Epub 2017 Jul 10.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275 Le Kremlin-Bicêtre, France; INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276 Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276 Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265 Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.032DOI Listing
September 2017

iRECIST: A clarification of tumour response assessment in the immunotherapy era.

Eur J Cancer 2017 05 4;77:165-167. Epub 2017 Apr 4.

Early Drug Development Unit (DITEP), Gustave Roussy, Paris Saclay University, Villejuif, France; INSERM U1015, Gustave Roussy, Paris Saclay University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.02.015DOI Listing
May 2017

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Oncoimmunology 2017 13;6(1):e1163456. Epub 2016 May 13.

Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, GRCC, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), GRCC, Villejuif, France; University of Paris Sud XI, Kremlin Bicêtre, France; Department of Immuno-Oncology, GRCC, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1163456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283624PMC
May 2016

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.

Cancer Discov 2017 02;7(2):128-130

Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1439DOI Listing
February 2017

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Clin Cancer Res 2017 04 8;23(8):1920-1928. Epub 2016 Nov 8.

Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2016/11/
Web Search
http://dx.doi.org/10.1158/1078-0432.CCR-16-1741DOI Listing
April 2017

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

J Thorac Oncol 2016 11 8;11(11):1819-1836. Epub 2016 Jun 8.

Medical Oncology Unit, University Hospital of Parma, Parma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.027DOI Listing
November 2016

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Eur J Cancer 2016 11 15;68:134-147. Epub 2016 Oct 15.

CHU Rennes, Service Hématologie Clinique, F-35033, Rennes, France; INSERM, U917, F-35043, Rennes, France. Electronic address:

View Article

Download full-text PDF

Source
http://www.ejcancer.com/article/S0959804916324315/pdf
Web Search
https://www.researchgate.net/publication/309184910_Turning_t
Web Search
https://linkinghub.elsevier.com/retrieve/pii/S09598049163243
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2016.09.010DOI Listing
November 2016

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.

Eur J Cancer 2016 10 18;66:91-4. Epub 2016 Aug 18.

Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.06.017DOI Listing
October 2016

Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis.

Oncoimmunology 2016 May 18;5(5):e1120399. Epub 2015 Dec 18.

Department of Medicine, Division of Oncology, Stanford University Medical Center , Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1120399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910756PMC
May 2016

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Eur J Cancer 2016 09 21;65:33-42. Epub 2016 Jul 21.

Université Paris-Saclay, Paris, France; Gustave Roussy, Université Paris-Saclay, Drug Development Department, Villejuif, F-94805, France; Gustave Roussy, Université Paris-Saclay, INSERM U981, Predictive Biomarkers and New Therapeutic Strategies in Oncology, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.05.031DOI Listing
September 2016

Holbrook Kohrt: In Memoriam (1977-2016).

Clin Cancer Res 2016 07;22(14):3695-6

Drug Development Department, INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1181DOI Listing
July 2016

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.

Clin Cancer Res 2016 Sep 7;22(17):4309-21. Epub 2016 Jul 7.

Faculté de Médicine, Université Paris Saclay, Université Paris-Sud, Le Kremlin Bicêtre, France. Inserm Unit U981, Gustave Roussy, Villejuif, France. DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0903DOI Listing
September 2016

Can immunostimulatory agents enhance the abscopal effect of radiotherapy?

Eur J Cancer 2016 07 18;62:36-45. Epub 2016 May 18.

Department of Radiation Oncology, SIRIC SOCRATES Gustave Roussy Cancer Campus, 114 rue E. Vaillant, 94800 Villejuif, France; Université Paris-Saclay, Faculté de Médecine, 94270 Kremlin Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France; DITEP, Gustave Roussy Cancer Campus, 114 rue E. Vaillant, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.067DOI Listing
July 2016

Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?

Oncoimmunology 2016 Apr 18;5(4):e1112942. Epub 2015 Dec 18.

INSERM, U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1112942DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839322PMC
April 2016

Prime time for immune-checkpoint targeted therapy at ASCO 2015.

Oncoimmunology 2016 Mar 12;5(3):e1068494. Epub 2015 Aug 12.

Gustave Roussy Cancer Campus, Villejuif, France; INSERM, U1015, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1068494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839368PMC
March 2016

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Bull Cancer 2016 May 28;103(5):484-98. Epub 2016 Mar 28.

Institut Gustave-Roussy, département de radiothérapie, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.02.014DOI Listing
May 2016

Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.

Eur J Cancer 2016 May 23;58:8-16. Epub 2016 Feb 23.

Department of Pharmacy, Henri Mondor University Hospitals, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.01.008DOI Listing
May 2016